如需更加详细的说明书文档，请联系右侧在线客服索取

使用目的：

本试剂盒用于测定血清、血浆及相关液体样本中的指标含量。

实验原理

本试剂盒应用双抗体夹心法测定标本中指标水平。用纯化的抗体包被微孔板，制成固相抗体，与HRP标记的抗体结合，形成抗体-抗原-酶标抗体复合物，经过彻底洗涤后加底物TMB显色。TMB在HRP酶的催化下转化成蓝色，并在酸的作用下转化成最终的黄色。颜色的深浅和样品中的指标呈正相关。用酶标仪在450nm波长下测定吸光度（OD值），通过标准曲线计算浓度。

试剂盒组成

1	30倍浓缩洗涤液	20ml×1瓶	7	终止液	6ml×1瓶
2	酶标试剂	6ml×1瓶	8	标准品	0.5ml×1瓶
3	酶标包被板	12孔×8条	9	标准品稀释液	1.5ml×1瓶
4	样品稀释液	6ml×1瓶	10	说明书	1份
5	显色剂A液	6ml×1瓶	11	封板膜	2张
6	显色剂B液	6ml×1/瓶	12	密封袋	1个

操作步骤

1. 标准品的稀释：本试剂盒提供原倍标准品一支，用户可在小试管中进行稀释。

2. 加样：分别设空白孔（空白对照孔不加样品及酶标试剂，其余各步操作相同）、标准孔、待测样品孔。在酶标包被板上标准品准确加样50μl，待测样品孔中先加样品稀释液40μl，然后再加待测样品10μl（样品最终稀释度为5倍）。加样将样品加于酶标板孔底部，尽量不触及孔壁，轻轻晃动混匀。

3. 温育：用封板膜封板后置37℃温育30分钟。   

4. 配液：将30倍浓缩洗涤液用蒸馏水30倍稀释后备用

5. 洗涤：小心揭掉封板膜，弃去液体，甩干，每孔加满洗涤液，静置30秒后弃去，如此重复5次，拍干。

6. 加酶：每孔加入酶标试剂50μl，空白孔除外。

7. 温育：操作同3。

8. 洗涤：操作同5。

9. 显色：每孔先加入显色剂A50μl，再加入显色剂B50μl，轻轻震荡混匀，37℃避光显色10分钟.

10. 终止：每孔加终止液50μl，终止反应（此时蓝色立转黄色）。

11. 测定：以空白孔调零，450nm波长依序测量各孔的吸光度（OD值）。 测定应在加终止液后15分钟以内进行。

文献参考：

  文章标题：β-Asarone, Tenuifolin, and YuanZhi Decoction Restore Cognitive Function and Modulate GRIN2B-Associated Autophagy in Alzheimer’s Disease

作者列表：Tang Haimin, Peng Fang, Shi Qian, Dai Xiaomin, Hou Feijun, Dong Haiying, Zhang Li, Shuai Zhifeng

影响因子：4.5

期刊：NEUROCHEMICAL RESEARCH

发表时间：2026-5-22

DOI:10.1007/s11064-026-04790-y

文献主题：Abstract

Alzheimer’s disease (AD) is characterized by neurodegeneration, autophagy dysregulation, and mitochondrial stress. β-asarone and tenuifolin have shown neuroprotective effects, but their mechanisms remain unclear. YuanZhi decoction, a traditional formula containing Polygala tenuifolia, is used for cognitive impairment, yet its active constituents are not fully understood. A D-galactose-induced AD mouse model (150 mg/kg/day, s.c., 42 days) was established to evaluate β-asarone, tenuifolin, their combination, and YuanZhi decoction. Behavioral tests (MWM and NOR), Nissl staining, IHC, network pharmacology, molecular docking (including the GRIN2B inhibitor ifenprodil as positive control), Western blotting, biochemical assays, and RT-qPCR were performed. All treatments improved cognitive function, attenuated hippocampal neuronal loss and tau pathology, and restored metabolic parameters (ATP, ROS, DT, SOD2). Network pharmacology identified GRIN2B as a key hub target. Molecular docking revealed that β-asarone and senegenin (the active metabolite of tenuifolin) bind to the same allosteric pocket as ifenprodil on GRIN2B, sharing highly consistent interaction residues. GRIN2B upregulation in AD mice was accompanied by autophagic dysfunction (increased LC3B/LC3A ratio and PINK1, reduced p62) and mitochondrial stress. These abnormalities were significantly reversed by all treatments, with the combination and YuanZhi decoction showing greater efficacy. β-asarone, tenuifolin, their combination, and YuanZhi decoction alleviate GRIN2B-linked autophagic imbalance and mitochondrial stress in AD-like mice, supporting their therapeutic potential.